Chak Sing Lau1, Faith Chia2, Andrew Harrison3, Tsu-Yi Hsieh4, Rahul Jain5, Seung Min Jung6, Mitsumasa Kishimoto7, Ashok Kumar8, Khai Pang Leong2, Zhanguo Li9, Juan Javier Lichauco10, Worawit Louthrenoo11, Shue-Fen Luo12, Peter Nash13, Chin Teck Ng14, Sung-Hwan Park6, Bagus Putu Putra Suryana15, Parawee Suwannalai16, Linda Kurniaty Wijaya17, Kazuhiko Yamamoto18, Yue Yang9, Swan Sim Yeap19. 1. Division of Rheumatology and Clinical Immunology, Queen Mary Hospital, University of Hong Kong, Hong Kong. 2. Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore City, Singapore. 3. Department of Medicine, University of Otago Wellington, Wellington South, New Zealand. 4. Section of Allergy, Immunology and Rheumatology, and Section of Clinical Skills Training, Taichung Veterans General Hospital, Taichung, Taiwan. 5. Narayana Hospital, Jaipur, India. 6. Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea, St. Mary's Hospital, Seoul, South Korea. 7. Immuno-Rheumatology Center, St Luke's International Hospital, Tokyo, Japan. 8. Department of Rheumatology, Fortis Flt. Lt Rajan Dhall Hospital, New Delhi, India. 9. Department of Rheumatology, Peking University People's Hospital, Beijing, China. 10. St. Luke's Medical Center, Quezon City, Philippines. 11. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 12. Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital and Chang Gung University, Tao-Yuan, Taiwan. 13. Department of Medicine, University of Queensland, Brisbane, Queensland, Australia. 14. Department of Rheumatology and Immunology, Singapore General Hospital, Singapore City, Singapore. 15. Rheumatology Division, Department of Internal Medicine, Brawijaya University, Saiful Anwar General Hospital, Malang, Indonesia. 16. Allergy, Immunology and Rheumatology Division, Internal Medicine Department, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 17. Division of Rheumatology, Department of Internal Medicine, University of Indonesia, Jakarta, Indonesia. 18. Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 19. Subang Jaya Medical Centre, Selangor, Malaysia.
Abstract
AIMS: Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritis patients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. MATERIALS AND METHODS: The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region. RESULTS: Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. CONCLUSION: The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries.
AIMS: Rheumatoid arthritis is a chronic inflammatory condition that affects approximately 1% of the world's population. There are a wide number of guidelines and recommendations available to support the treatment of rheumatoid arthritis; however, the evidence used for these guidelines is predominantly based on studies in Caucasian subjects and may not be relevant for rheumatoid arthritispatients in the Asia-Pacific region. Therefore, the Asia Pacific League of Associations for Rheumatology established a Steering Committee in 2013 to address this issue. MATERIALS AND METHODS: The AGREE II instrument and the ADAPTE Collaboration framework were applied to systematically identify, appraise, synthesize, and adapt international rheumatoid arthritis guidelines for use in the Asia-Pacific region. RESULTS: Forty rheumatoid arthritis treatment recommendations, based on evidence and expert opinion, were drafted and are presented in this report. CONCLUSION: The Asia Pacific of Associations for Rheumatology rheumatoid arthritis treatment recommendations are intended to serve as a reference for best practice management of rheumatoid arthritis in Asia-Pacific, focusing on local issues to ensure the delivery of basic care for these patients, and to improve their outcomes. In addition, the document will serve as a reference for national rheumatology associations in Asia-Pacific for developing guidelines in their respective countries.
Authors: Karel Pavelka; Nurullah Akkoç; Mustafa Al-Maini; Cristiano A F Zerbini; Dmitry E Karateev; Evgeny L Nasonov; Mahboob U Rahman; Ronald Pedersen; Andrew Dinh; Qi Shen; Radu Vasilescu; Sameer Kotak; Ehab Mahgoub; Bonnie Vlahos Journal: Rheumatol Int Date: 2017-06-09 Impact factor: 2.631